The $30 million Series A-3 financing consists of a $24 million first close completed in August 2024 and a $6 million second close completed in August 2025. In addition, SEED has received close to $60 ...

BPGbio Inc., a leading biology-first, AI-powered, clinical stage biopharma focused on mitochondrial biology and protein homeostasis, today announced that Slava Akmaev, Ph.D., a seasoned AI-biotech ...

The event will provide an update on the Company's plans for Phase 2 studies and data from the full Phase 1/2 dose expansion cohort, including from the ESMO oral presentation on Friday, October 17th.

Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced its recognition by both Endpoints News and Fierce ...

These scaling investments align with the Weston Family Foundation’s mission to catalyze innovation in health research, particularly in areas where initial funding has shown promising results. By ...

The sessions will be webcast and can be accessed by visiting the Events section of the Altimmune website.

World BI delivers Drug Discovery Conferences for scientists, sponsors, engineers, and exhibitors from the pharma, biotech, life sciences, healthcare, and bioinformatics industries. These Drug ...

“Oktoberfest is a cherished time for craft beer fans,” said Prinz Pinakatt, Chief Growth Officer at Tilray Beverages. “Our ...

Part A results demonstrated efficacy and safety; ATSN-201 on track to be first gene therapy and one-time treatment for XLRS DURHAM, N.C., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Atsena Therapeutics, a ...

UK and international labs can enroll in this EQA program (code POCT CYP2C19) via EMQN CIC at https://www.emqn.org/our-eqa-schemes/ and enquiries about Microbix QAPs can be directed to customer.service ...

Castle is among just 89 companies honored with a Greater Pittsburgh Top Workplaces award in 2025. This distinction adds to eight other Top Workplaces accolades the Company has received this year: Top ...

Open-label study evaluated a two-dose induction regimen of BPL-003 (8 mg followed by 12 mg two weeks later) in patients with ...